News and How Much to Improve in the Management of Soft Tissue Sarcomas (2nd Edition)

Dear Colleagues,

The Special Issue is a continuation of our previous Special Issue, “News and How Much to Improve in Management of Soft Tissue Sarcomas”.

Soft tissue sarcomas (STSs) are rare, heterogeneous (>150 subtypes), and of mesenchymal origin. They represent less than 1% of adult tumors and can be located anywhere in the body. Under these conditions, a multidisciplinary approach to sarcomas is mandatory. In recent decades, due to advancements in chemotherapy and surgical techniques, the survival rate has reached approximately 50% among patients with sarcoma. However, survival rates have not improved in the last 20 years. New biomarkers and therapeutic strategies are necessary to further improve prognosis. Likewise, focusing on these patients in reference centers is of vital importance in ensuring both a correct diagnosis and a personalized treatment that correctly incorporates new diagnostic–therapeutic technologies, and thus improving the medium- and long-term prognosis of these patients.

We are pleased to invite you to collaborate in this Special Issue of soft tissue sarcomas.

This Special Issue will explore how the sarcomas subgroup relates to the scope of the journal.

In this Special Issue, we propose an approach to recent progress made in the diagnosis and treatment, as well as the greater impact on the prognosis, of the most prevalent subtypes of sarcomas. Original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: immunotherapy in sarcomas, IA and sarcomas; 3D imaging in sarcomas; new surgical approaches to sarcomas; pelvic sarcomas; sarcomas of the cava veins and others venous locations; retroperitoneal sarcomas; medical facilities and reference centers for sarcomas; treatment of desmoid tumors; treatment approaches to metastatic sarcomas; the state-of-the-art in the medical management of sarcomas.

We look forward to receiving your contributions.

Dr. Vicente Artigas-Raventós
Dr. José Manuel Asencio
Dr. Christina L. Roland
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.